Hyperthermia and Tumor Immunity

Abstract

Thermal ablation is a cornerstone in the management of cancer patients. Typically, ablation procedures are performed for patients with a solitary or oligometastatic disease with the intention of eradicating all sites of the disease. Ablation has traditionally played a less prominent role for patients with a widely metastatic disease. For such patients, attempting to treat numerous sites of disease compounds potential risks without a clear clinical benefit and, as such, a compelling justification for performing an intervention that is unlikely to alter a patient’s clinical trajectory is uncommon. However, the discovery of immune checkpoints and the development of immune checkpoint inhibitors have brought a new perspective to the relevance of local cancer therapies such as ablation for patients with a metastatic disease. It is becoming increasingly apparent that local cancer therapies can have systemic immune effects. Thus, in the new perspective of cancer care centered upon immunologic principles, there is a strong interest in exploring the utility of ablation for patients with a metastatic disease for its immunologic implications. In this review, we summarize the unmet clinical need for adjuvant interventions such as ablation to broaden the impact of systemic immunotherapies. We additionally highlight the extant preclinical and clinical data for the immunogenicity of common thermal ablation modalities.

Computational Modeling of Combination of Magnetic Hyperthermia and Temperature-Sensitive Liposome for Controlled Drug Release in Solid Tumor

“…The same conclusion has been reached in previous studies on the inadequacy of the heating zone due to thermal ablation or hyperthermia for large tumors [39,84,85]. An examination of the results of the two above-mentioned methods reveals that MHT is not able to eradicate cancer cells on the edge of the tumor; additionally, conventional Dox chemotherapy has been shown to have poor drug penetration.…”

Response of human glioblastoma cells to hyperthermia: Cellular apoptosis and molecular events

“…Temperature level is a challenge for hyperthermia of clinical studies, as 41.8˚C is used for wholebody temperature in humans, high temperatures such as 4245˚C strikes a problem and advanced equipment is required [26]. However, results of several studies of hyperthermia don't support the inducing of anti-tumor effects, but one research demonstrated that hyperthermia at 3941˚C for 90 min could in fact induce cellular and humoral antitumor reactions [49]. According to current clinical status, hyperthermia would damage normal brain tissue at higher temperatures (45˚C) [50].…”

Deciphering Repertoire of B16 Melanoma Reactive TCRs by Immunization, In Vitro Restimulation and Sequencing of IFNγ-Secreting T Cells

“…We used heat-shocked tumor cells due to the notion that lysate of unstressed cells does not induce noticeable immune response or even can be immunosuppressive [ 33 , 34 ]. Heat shock is known to enhance antigenicity and immunogenicity by a bunch of mechanisms [ 35 , 36 ]. Here, we fractionated lysed cells and conditioned medium (see Section 4.6 ) in order to exclude crude cell mass and to ensure the absence of viable tumor cells.…”